Cargando…

Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia?

Detalles Bibliográficos
Autores principales:	Perner, Anders, Venkatesh, Balasubramanian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097504/ https://www.ncbi.nlm.nih.gov/pubmed/37060914 http://dx.doi.org/10.1016/S0140-6736(23)00587-1

Ejemplares similares

Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID‐19 and severe hypoxaemia—Post hoc exploratory analyses of the COVID STEROID 2 trial
por: Granholm, Anders, et al.
Publicado: (2022)

Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
por: Granholm, Anders, et al.
Publicado: (2022)

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
por: Matthay, Michael A, et al.
Publicado: (2020)

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial
por: Granholm, Anders, et al.
Publicado: (2021)

After 62 years of regulating immunity, dexamethasone meets COVID-19
por: Cain, Derek W., et al.
Publicado: (2020)

Dilemma of countering happy hypoxaemia COVID-19 patients
por: Kobayashi, Keigo, et al.
Publicado: (2021)

Conservative management of COVID-19 associated hypoxaemia
por: Supady, Alexander, et al.
Publicado: (2021)

Conservative management of COVID-19 associated hypoxaemia
por: Windisch, Wolfram, et al.
Publicado: (2021)

Conservative management of COVID-19 associated hypoxaemia
por: Voshaar, Thomas, et al.
Publicado: (2021)

Conservative management of COVID-19 associated hypoxaemia
por: Voshaar, Thomas, et al.
Publicado: (2021)

Conservative management of COVID-19 associated hypoxaemia
por: Voshaar, Thomas, et al.
Publicado: (2021)

Higher PEEP in intubated COVID-19-associated ARDS patients? We are not sure
por: Yaroshetskiy, Andrey I., et al.
Publicado: (2022)

How likely are COVID-19 interventions to benefit the sickest patients?
por: Perner, Anders, et al.
Publicado: (2020)

Long-term mortality and health-related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia
por: Crescioli, Elena, et al.
Publicado: (2022)

Challenges in operationalising clinical trials in India during the COVID-19 pandemic
por: Bassi, Abhinav, et al.
Publicado: (2022)

Lower versus higher oxygenation targets in critically ill patients with severe hypoxaemia: secondary Bayesian analysis to explore heterogeneous treatment effects in the Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU) trial
por: Klitgaard, Thomas L., et al.
Publicado: (2022)

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
por: So-Osman, Cynthia, et al.
Publicado: (2022)

Hypoxaemia in COVID-19: many pieces to a complex puzzle
por: Busana, Mattia, et al.
Publicado: (2022)

A Higher Number of Covid19 Cases and Fatalities in Israel Phased With the Start of the Mass Vaccination
por: Boretti, Alberto
Publicado: (2021)

Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia
por: Blette, Bryan S., et al.
Publicado: (2023)

Safety of COVID-19 booster dose: is the juice worth the squeeze?
por: Madhi, Shabir A, et al.
Publicado: (2023)

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

Hypoxaemia in a pregnant lady
por: Yamin, Hasan S., et al.
Publicado: (2016)

Impact of methotrexate on first-dose COVID-19 mRNA vaccination
por: Connolly, Caoilfhionn M, et al.
Publicado: (2021)

Hypoxaemia in the early stage of COVID-19: prevalence of physical or biochemical factors?
por: Harutyunyan, Gurgen, et al.
Publicado: (2022)

Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”
por: Picardi, Marco, et al.
Publicado: (2021)

Hyperoxaemia and hypoxaemia are associated with harm in patients with ARDS
por: Boyle, Andrew J., et al.
Publicado: (2021)

Hospital admissions due to COVID-19 in Scotland after one dose of vaccine
por: Dean, Natalie
Publicado: (2021)

Ventilation/perfusion mismatch is not the sole reason for hypoxaemia in early stage COVID-19 patients
por: Harutyunyan, Gurgen, et al.
Publicado: (2022)

Comment on “Dexamethasone Inhibits Spheroid Formation of Thyroid Cancer Cells Exposed to Simulated Microgravity”
por: Bevelacqua, Joseph J., et al.
Publicado: (2020)

Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT
por: Lang, Min, et al.
Publicado: (2020)

COVID-19 mRNA vaccination and myocarditis or pericarditis
por: Husby, Anders, et al.
Publicado: (2022)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Low-dose radiation, scientific scrutiny, and requirements for demonstrating effects
por: Møller, Anders Pape, et al.
Publicado: (2013)

Number needed to vaccinate for COVID-19 booster doses: a valuable metric to inform vaccination strategies
por: Feng, Shuo, et al.
Publicado: (2023)

Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
por: Hung, Ivan F N, et al.
Publicado: (2021)

Tolerability of prone positioning in non‐intubated patients with hypoxaemia due to COVID‐19‐related pneumonia
por: Shikano, Kohei, et al.
Publicado: (2022)

COVID-19 vaccines and kidney disease
por: Windpessl, Martin, et al.
Publicado: (2021)

Hospitalised COVID-19 outcomes are predicted by hypoxaemia and pneumonia phenotype irrespective of the timing of their emergence
por: Salter, Brittany, et al.
Publicado: (2022)

Updated report of COVID-19 vaccine safety monitoring in Japan: booster doses for Omicron variants and vaccinations for infants and young children
por: Yamaguchi, Toshihiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1pbg6bi6rv0o64rlea4uf7omar